Degrading the anaplastic lymphoma kinase protein to treat paediatric cancers
Dr Lizzie Tucker will assess a new type of treatment to fight ALK-driven childhood cancers like neuroblastoma.
Creating advanced models to test new treatments for malignant rhabdoid tumours
Dr Daniel Williamson’s expert team will find the best malignant rhabdoid tumour models to test exciting new treatments.
Developing a new drug for the treatment of ALT-positive cancers
Dr Jon Elkins and Dr Anna Rose at the University of Oxford hope to develop a new drug which will affect vital ALT-positive cancer cell processes.
Finding the best way to make two cancer-targeting T cells for the price of one
Professor John Anderson at University College London hopes to develop a cost-effective CAR T-cell combination therapy.
Investigating a new type of drug that can inhibit the growth and survival of neuroblastoma and other childhood cancers
Professor Karim Malik and Dr Jodie Bojko are testing drugs that can prevent cancer cells from making growth-promoting proteins.
Making CAR-T cells that can rest to improve their cancer-fighting ability
Professor John Anderson’s team at University College London Great Ormond Street Institute of Child Health aim to revolutionise CAR T-cell therapy for solid tumours.
A new approach to deliver chemotherapy directly into brain tumours
Professor Rylie Green at Imperial College London will test a device that can deliver chemotherapy directly to brain tumours, sparing healthy cells.
Investigating the role of SET in childhood acute myeloid leukaemia to develop new treatments
Dr Maria Teresa Esposito hopes to learn more about a gene called SET in leukaemia and will test the best medicines to fight it.
Targeting metabolism in aggressive childhood blood cancers
Prof Jonathan Bond and Dr Marie-Claire Fitzgerald aim to find a treatment that can exploit a key weakness of acute myeloid leukaemia.